Loqtorzi Extends Survival in HER2-Positive Advanced Urothelial Cancer
Supplemental Xtandi Does Not Improve Metastasis-Free Survival in High-Risk Prostate Cancer
Imfinzi With Chemo Produces Inconclusive Outcomes in Phase 3 Mesothelioma Study
Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer